Specify a stock or a cryptocurrency in the search bar to get a summary
Plus Therapeutics Inc
PSTVPlus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. Address: 4200 Marathon Boulevard, Austin, TX, United States, 78756
Analytics
WallStreet Target Price
32.75 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures PSTV
Dividend Analytics PSTV
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History PSTV
Stock Valuation PSTV
Financials PSTV
Results | 2019 | Dynamics |